التفاصيل البيبلوغرافية
| العنوان: |
INACTIVATION OF SMOOTH MUSCLE TISSUE |
| Document Number: |
20110184330 |
| تاريخ النشر: |
July 28, 2011 |
| Appl. No: |
13/018713 |
| Application Filed: |
February 01, 2011 |
| مستخلص: |
Treatment and procedures for treating bodily conduits involves deactivating, killing, or otherwise treating smooth muscle tissue of the conduit. |
| Inventors: |
LAUFER, Michael D. (Menlo Park, CA, US); AUTH, David C. (Kirkland, WA, US); DANEK, Christopher J. (Santa Clara, CA, US); WIZEMAN, William J. (Menlo Park, CA, US); KAPLAN, Gary S. (San Francisco, CA, US) |
| Assignees: |
Asthmatx, Inc. (Sunnyvale, CA, US) |
| Claim: |
1. A method of reducing the ability of a body passage to narrow, the method comprising: placing an agent into a blood vessel that supplies blood to tissue of the body passage, where the agent affects the ability of the body passage to constrict. |
| Claim: |
2. The method of claim 1, where the body passage comprises an airway within the lung. |
| Claim: |
3. The method of claim 1, where the blood vessel comprises a bronchial artery. |
| Claim: |
4. The method of claim 1, where the agent comprises an agent that selectively affects airway smooth muscle tissue. |
| Claim: |
5. The method of claim 1, where the agent comprises an agent selected from a group consisting of a toxin, a radioactive agent, a viral agent, and a drug. |
| Claim: |
6. The method of claim 5, where the agent comprises botulinum toxin type A. |
| Claim: |
7. The method of claim 5, where the agent is selected from a group consisting of an artificial toxin, and a naturally occurring toxin. |
| Claim: |
8. The method of claim 1, further comprising delivering a second agent to the body, where the second agent protects a portion of the body against the effects of the agent. |
| Claim: |
9. The method of claim 8, where the second agent is delivered by a mode selected from the group consisting of inhalation, injection, and oral administration. |
| Claim: |
10. The method of claim 1, where the agent blocks flow of blood within the blood vessel resulting in damage to smooth muscle. |
| Claim: |
11. The method of claim 1, further comprising stimulating the body passage. |
| Claim: |
12. The method of claim 11, where stimulating the body passage increases absorption of the agent. |
| Claim: |
13. The method of claim 11, where placing the agent comprises injecting the agent in response to the amount of stimulated contraction. |
| Claim: |
14. The method of claim 1, further comprising selecting a second vascular site, and reducing blood flow in the second vascular site to decrease the flow rate of the agent in the blood vessel. |
| Claim: |
15. The method of claim 1, further comprising monitoring the blood to determine an amount the agent remaining in the blood supply. |
| Claim: |
16. A method of reducing the ability of a body passage to constrict in response to stimulus, the method comprising: altering a blood supply of smooth muscle tissue in the body passage to lessen or eliminate the ability of a portion of the smooth muscle tissue to constrict the body passage. |
| Claim: |
17. The method of claim 16, where the body passage comprises an airway within the lung. |
| Claim: |
18. The method of claim 16, where altering the blood supply comprises placing an agent directly into a blood vessel that carries the blood supply. |
| Claim: |
19. The method of claim 18, where the blood vessel comprises a bronchial artery. |
| Claim: |
20. The method of claim 16, where altering the blood supply comprises shunting the blood supply to a location distal of the smooth muscle tissue. |
| Claim: |
21. The method of claim 16, where altering the blood supply comprises ligating a blood vessel that carries the blood supply. |
| Claim: |
22. The method of claim 16, where altering the blood supply comprises, delivering an agent into the body passage, where a portion of the agent is eventually carried to the smooth muscle tissue. |
| Claim: |
23. The method of claim 16, where the agent comprises an agent that selectively affects airway smooth muscle tissue. |
| Claim: |
24. The method of claim 16, where the agent comprises an agent selected from a group consisting of a toxin, a radioactive agent, a viral agent, and a drug. |
| Claim: |
25. The method of claim 24, where the agent comprises botulinum toxin type A. |
| Claim: |
26. The method of claim 24, where the agent is selected from a group consisting of an artificial toxin, and a naturally occurring toxin. |
| Claim: |
27. The method of claim 18, further comprising delivering a second agent to the body, where the second agent protects a portion of the body against the effects of the agent. |
| Claim: |
28. The method of claim 27, where the second agent is delivered by a mode selected from the group consisting of inhalation, injection, and oral administration. |
| Claim: |
29. The method of claim 18, where the agent blocks flow of blood within the blood vessel to damage smooth muscle. |
| Claim: |
30. The method of claim 18, further comprising stimulating the body passage. |
| Claim: |
31. The method of claim 30, where stimulating the body passage increases absorption of the agent. |
| Claim: |
32. The method of claim 18, further comprising selecting a second vascular site, and reducing blood flow in the second vascular site to decrease the flow rate of the agent in the blood vessel. |
| Claim: |
33. The method of claim 18, further comprising monitoring the blood to determine an amount the agent remaining in the blood supply. |
| Claim: |
34-47. (canceled) |
| Current U.S. Class: |
604/8 |
| Current International Class: |
61; 61; 61; 61; 61 |
| رقم الانضمام: |
edspap.20110184330 |
| قاعدة البيانات: |
USPTO Patent Applications |